June 2012

Covance’s Patrick McConville, Ph.D and James Mobley Ph.D., Founder and CSO, Sunapten Therapeutics, Inc. discussed how advances in the understanding of the pathophysiology of human inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease have been aided by the development of clinically translatable animal models, and increasingly sophisticated means of assessing drug efficacy in those models.

Download Resource